Description
Lesofavumab is a Recombinant monoclonal antibody to Influenza B virus hemagglutinin. Lesofavumab is a human monoclonal antibody that can be potentially used in the treatment of Influenza B infection. Genentech, a subsidiary of Roche, is developing lesofavumab (RG 6024), a monoclonal antibody, for the treatment of influenza B infections.
Catalog No.
DVV03805
Host species
Homo sapiens
Species reactivity
Influenza B virus
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Concentration
1 mg/ml
Purity
>95% by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1, kappa
Applications
Research Grade Biosimilar
Target
HA/Hemagglutinin
Purification
Protein A or G purified from cell culture supernatant.
Endotoxin level
Please contact with the lab for this information.
Expression system
XtenCHO
Accession
P03461
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Alternative Names
RG6024, RG 6024, MHAB5553A, RG70026, RO7045557, CAS: 1807960-57-1, Influenza Virus (Flu)
Note
For research use only. Not suitable for clinical or therapeutic use.
關鍵字： Lesofavumab;DVV03805;HA/Hemagglutinin;
武漢佰樂博生物（Biolab Reagents）由五位畢業(yè)于華中科技大學，華中農業(yè)大學，武漢大學等知名高校，且具有二十年工作經驗的生命科學領域頂級研究者創(chuàng)立于2021年，憑借豐富的產品開發(fā)經驗，利用全球領先的技術平臺，引進和整合全球高品質的蛋白、抗體和試劑盒產品。目前，佰樂博生物作為法國AntibodySystem和ProteoGenix在亞洲的獨家總代理，提供近30,000種生命科學試劑，核心產品涵蓋蛋白、抗體和試劑盒，旨在為科研工作者提供專業(yè)、全面、可靠的試劑支持，推動生命科學研究的深入發(fā)展。